Cochrane · systematic review · CD002062

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy

Hughes, RAC, Mehndiratta, MM, Rajabally, YA · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library

Neuromuscular3 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 4 · 33.3%Low 3 · 25%Moderate 3 · 25%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Prednisone for chronic inflammatory demyelinating polyradiculoneuropathy

Population: people with chronic inflammatory demyelinating polyradiculoneuropathy
CD002062.PUB4 (current) · 5 questions
OutcomeEffectEvidenceStatus / GRADE
Change in disability after one year
no estimate extractedNRNo studies
Change in impairment after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280)
no estimate extracted1 study · 28 participantsVery low
Downgraded: risk of bias, imprecision
Change in impairment after 12 weeks (including those who did not complete the study) NIS (range 0 to 280)
no estimate extracted1 study · 35 participantsVery low
Downgraded: risk of bias, imprecision
Number of participants improved after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280)
RR 2.41 study · 28 participantsVery low
Downgraded: risk of bias, imprecision
Number of participants improved after 12 weeks (including those who did not complete the study) NIS (range 0 to 280)
RR 2.021 study · 35 participantsVery low
Downgraded: risk of bias, imprecision

Monthly pulsed high‐dose dexamethasone compared to oral prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

Population: people with chronic inflammatory demyelinating polyradiculoneuropathy
CD002062.PUB4 (current) · 7 questions
OutcomeEffectEvidenceStatus / GRADE
Change in disability after one year
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extractedNRNo studies
Remission at 12 months
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 1.111 study · 40 participantsModerate
Downgraded: imprecision
≥ 1 point improvement on INCAT disability score at 12 months
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 1.241 study · 40 participantsLow
Downgraded: imprecision, indirectness
Change in impairment: change in MRC sum score at endpoint4
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 study · 39 participantsLow
Downgraded: imprecision, indirectness
Change in impairment: change in grip strength at endpoint4
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 study · 38 participantsModerate
Downgraded: imprecision
Sleeplessness
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 0.441 study · 40 participantsLow
Downgraded: imprecision, indirectness
Moon facies
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 0.481 study · 40 participantsModerate
Downgraded: imprecision, indirectness

Prednisone for chronic inflammatory demyelinating polyradiculoneuropathy

Population: people with chronic inflammatory demyelinating polyradiculoneuropathy
CD002062.PUB3 · 4 questions
OutcomeEffectEvidenceStatus / GRADE
Improvement in impairment after 12 weeks (excluding those who did not complete the study) Neuropathy impairment score (range 0 to 280)
no estimate extracted1 study · 28 participantsVery low
Downgraded: risk of bias
Improvement in impairment after 12 weeks (including those who did not complete the study) Neuropathy impairment score (range 0 to 280)
no estimate extracted1 study · 35 participantsVery low
Downgraded: risk of bias
Number of patients improved after 12 weeks (excluding those who did not complete the study) Neuropathy impairment score (range 0 to 280)
RR 2.41 study · 28 participantsVery low
Downgraded: risk of bias
Number of patients who showed improvement after 12 weeks (including those who did not complete the study) Neuropathy impairment score (range 0 to 280)
RR 2.021 study · 35 participantsVery low
Downgraded: risk of bias

Monthly pulsed high‐dose dexamethasone compared to oral prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

Population: people with chronic inflammatory demyelinating polyradiculoneuropathy
CD002062.PUB3 · 7 questions
OutcomeEffectEvidenceStatus / GRADE
Remission at 12 months
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 1.111 study · 40 participantsModerate
≥ 1 point improvement on INCAT disability score at 12 months
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 1.241 study · 40 participantsModerate
Change in MRC sum score
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 study · 39 participantsHigh
Change in grip strength
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 study · 38 participantsHigh
Sleeplessness
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 0.441 study · 40 participantsHigh
Moon facies
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 0.481 study · 40 participantsHigh
Wide 95% CI.
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 participantsUngraded

Prednisone for chronic inflammatory demyelinating polyradiculoneuropathy

Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
CD002062.PUB2 · 4 questions
OutcomeEffectEvidenceStatus / GRADE
Improvement in impairment after 12 weeks (excluding those who did not complete the study) Neuropathy impairment score (range 0 to 280)
no estimate extracted1 study · 28 participantsVery low
Downgraded: risk of bias
Improvement in impairment after 12 weeks (including those who did not complete the study) Neuropathy impairment score (range 0 to 280)
no estimate extracted1 study · 35 participantsVery low
Downgraded: risk of bias
Number of patients improved after 12 weeks (excluding those who did not complete the study) Neuropathy impairment score (range 0 to 280)
RR 2.41 study · 28 participantsVery low
Downgraded: risk of bias
Number of patients who showed improvement after 12 weeks (including those who did not complete the study) Neuropathy impairment score (range 0 to 280)
RR 2.021 study · 35 participantsVery low
Downgraded: risk of bias

Monthly pulsed high‐dose dexamethasone compared to oral prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

Population: patients with chronic inflammatory demyelinating polyradiculoneuropathy
CD002062.PUB2 · 7 questions
OutcomeEffectEvidenceStatus / GRADE
Remission at 12 months
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 1.111 study · 40 participantsModerate
≥ 1 point improvement on INCAT disability score at 12 months
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 1.241 study · 40 participantsModerate
Change in MRC sum score
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 study · 39 participantsHigh
Change in grip strength
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 study · 38 participantsHigh
Sleeplessness
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 0.441 study · 40 participantsHigh
Moon facies
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
RR 0.481 study · 40 participantsHigh
Wide 95% CI.
Monthly pulsed high‐dose dexamethasone vs oral prednisolone
no estimate extracted1 participantsUngraded